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Editorial on the Research Topic
Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases
Written by researchers brought together by COST Action CM1103 to address multi-target drug
design for the complex challenge of neuropathology, the interdisciplinary reviews span the range
from computational enzymology through medicinal chemistry and pharmacology to human
studies.
To introduce the process of designing drugs that hit the multiple targets identified as important
complex neuropathologies, Hughes et al. present a brief overview of the current approaches of
approaches of data-mining, in silico screening, and rational drug design that rely heavily on clinical
and biological validation of suitable targets and the molecular understanding of these targets by
their crystallographic structures. Computational advances have been particularly important in the
last 5 years, tackling the workload required for multiple targets. Nikolic et al. used data-mining
to search for off-target activities, followed by docking compounds to targets to assess their
potential as ligands, to provide new leads for experimental confirmation and optimization. Through
cheminformatic, 3D-QSAR and virtual screening methodologies, ligands were identified for the
traditional neurotransmitter breakdown enzymes, cholinesterases and monoamine oxidases, that
also bind to combinations of dopamine, serotonin and histamine receptors, a vital contribution
to efficiency in the rational design of multipotent ligands with selected polypharmacology. The
next article moves into molecular dynamics on receptors where ligand binding can increase or
decrease the response of the receptor, and on to ion channels and their conformational changes
responsible for gating. Vianello et al. also review the investigations on the critical chemical step in
the inactivation of monoamine oxidase B by selegiline, using a combination of the high-resolution
quantum mechanical calculations with molecular mechanics (multiscale QM/MM simulation).
Reviewing a hotly-debated topic, the article gives a clear exposition of the evidence for a hydride
mechanism for monoamine oxidases.
Although computational methods have accelerated compound discovery, lead compounds
must still be synthesized. Marco-Contelles et al. describe the optimization of a compound
designed to inhibit multiple targets in Alzheimer’s disease, showing the derivation of ASS234 from
single-target ligands and its assessment, including inhibition of cholinesterases and monoamine
oxidases, antioxidant properties, low toxicity and suitable permeability. In vivo, ASS234 proved
to be neuroprotective and to prevent β-amyloid aggregation in a mouse model. The medicinal
chemistry theme continues with two articles on drug design for receptors. Khanfar et al. focus
on combinations with antagonists of the histamine H3 receptor. H3R plays an important role
as a hetero-receptor in the modulation of the release of other neurotransmitters including
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acetylcholine, noradrenaline, dopamine, GABA, glutamate, and
serotonin. Thus, antagonists may have a therapeutic role in
preventing negative feedback on neurotransmitters known to
be involved in depression, schizophrenia, and Alzheimer’s
Disease. The authors discuss the challenges and target choice
(other receptors, transporters, or enzymes such as histamine
N-methyl transferase) in designing combinations for these
receptors. Maramai et al. explore the therapeutic importance
of D3 antagonists or partial agonists and examine possible
combinations that would be useful in the dysregulation of the
dopamine neurotransmitter system linked to schizophrenia. A
complexity in multi-target design for these G-protein coupled
receptors is that many of them form heterodimers (such as H3
with D2, mentioned in Khanfar et al.). In particular, D3 receptors
can form homodimers or heteromers with D1 or D2 receptors,
modulating the response to ligands. The authors then review
recent compound discovery on a variety of innovative scaffolds
for attaining high D3 receptor affinity and selectivity over the D2
receptors.
The next two articles address molecular pharmacology.
Unzeta et al. consider how one specific multi-target designed
ligand (MTDL) addresses a selection of the multiple possible
targets in Alzheimer’s disease. ASS234 was designed from
donepezil, a cholinesterase inhibitor used in the clinic, and
an inhibitor of monoamine oxidase B, of the same propargyl
type as deprenyl. Derivatives of ASS234 were designed to
improve affinity to the enzyme targets and to incorporate metal
ion binding and antioxidant properties, two important targets
in preventing cell death in the brain. The pharmacology of
the targets is also reviewed to explain why action at these
targets is needed. In particular, the role of metal ions and
of inflammation in brain pathology is reviewed as these are
more complex target areas than enzymes and receptors. Ramsay
et al. consider the biochemical pharmacology used to evaluate
the new multi-target compounds against the accepted enzyme
targets, including cholinesterases and monoamine oxidases, and
then review new targets in mitochondrial function. Advances
in cell biology have demonstrated that mitochondrial fission
and fusion is a protective mechanism in cellular bioenergetics.
Regulation of these processes is therefore emerging as a target for
new therapeutic strategies to prevent neurodegeneration. Finally,
drug metabolism by the cytochrome P450 system, a vital part of
any compound evaluation, is also reviewed.
Moving on to in vivo work, Di Giovanni et al. discuss
neuropharmacological studies on treatments for and novel
compounds designed to tackle schizophrenia, depression, and
obesity, conditions where monoamines have been implicated.
The monoamine pathways include dopaminergic neurons in the
ventral tegmental area and the substantia nigra pars compacta,
noradrenergic neurons arising from locus coeruleus, serotonergic
neurons originating from median and dorsal raphe nuclei, and
histaminergic neurons from the hypothalamus. The authors use
an excellent figure to summarize the biosynthesis, metabolism,
receptors and transporters of these systems, before discussing
known drugs and why consideration of the monoamine systems
is important in neurological conditions such as epilepsy,
Alzheimer’s Disease and stroke. Epilepsy is considered in more
depth by Svob Strac et al., who propose that monoaminergic
multitarget drugs could provide a therapeutic opportunity.
Drawing from experimental, clinical, and genetic studies in
animals and humans, they consider each of the monoamine
systems, summarizing the evidence to identify key proteins as
targets in epilepsy providing a basis for future monoaminergic
strategies to treat epilepsy by recognizing it as an imbalance
of brain chemicals and physiology due a multitude different
mechanisms, requiring multi-target drugs.
In conclusion, to identify successful multi-target compounds,
extensive pharmacological characterization is essential, as is the
ability to learn about the drug-target interactions from the large
amount of data being generated. However, which combinations
of targets will be effective is still a big question.
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